M-GEAR: Gateway-Based Energy-Aware Multi-Hop Routing Protocol for WSNs

In this research work, we advise gateway based energy-efficient routing protocol (M-GEAR) for Wireless Sensor Networks (WSNs). We divide the sensor nodes into four logical regions on the basis of their location in the sensing field. We install Base Station (BS) out of the sensing area and a gateway node at the centre of the sensing area. If the distance of a sensor node from BS or gateway is less than predefined distance threshold, the node uses direct communication. We divide the rest of nodes into two equal regions whose distance is beyond the threshold distance. We select cluster heads (CHs)in each region which are independent of the other region. These CHs are selected on the basis of a probability. We compare performance of our protocol with LEACH (Low Energy Adaptive Clustering Hierarchy). Performance analysis and compared statistic results show that our proposed protocol perform well in terms of energy consumption and network lifetime.Comment: IEEE 8th International Conference on Broadband and Wireless Computing, Communication and Applications (BWCCA'13), Compiegne, Franc

Oxidative stress contributes to cobalt oxide nanoparticles-induced cytotoxicity and DNA damage in human hepatocarcinoma cells.

BackgroundCobalt oxide nanoparticles (Co(3)O(4)NPs) are increasingly recognized for their utility in biological applications, magnetic resonance imaging, and drug delivery. However, little is known about the toxicity of Co(3)O(4)NPs in human cells.MethodsWe investigated the possible mechanisms of genotoxicity induced by Co(3)O(4)NPs in human hepatocarcinoma (HepG2) cells. Cell viability, reactive oxygen species (ROS), glutathione, thiobarbituric acid reactive substance, apoptosis, and DNA damage were assessed in HepG2 cells after Co(3)O(4)NPs and Co(2+) exposure.ResultsCo(3)O(4)NPs elicited a significant (P < 0.01) reduction in glutathione with a concomitant increase in lipid hydroperoxide, ROS generation, superoxide dismutase, and catalase activity after 24- and 48-hour exposure. Co(3)O(4)NPs had a mild cytotoxic effect in HepG2 cells; however, it induced ROS and oxidative stress, leading to DNA damage, a probable mechanism of genotoxicity. The comet assay showed a statistically significant (P < 0.01) dose- and time-related increase in DNA damage for Co(3)O(4)NPs, whereas Co(2+) induced less change than Co(3)O(4)NPs but significantly more than control.ConclusionOur results demonstrated that Co(3)O(4)NPs induced cytotoxicity and genotoxicity in HepG2 cells through ROS and oxidative stress

Improvement of Abiotic Stress Tolerance in Plants with the Application of Nanoparticles

Plants are under the threat of climatic changes and there is a reduction in productivity and deterioration in quality. The application of nanoparticles is one of the recent approaches to improve plant yield and quality traits. A number of nanoparticles, such as zinc nanoparticles (ZnO NPs), iron nanoparticles (Fe2O3 NPs), silicon nanoparticles (SiO2 NPs), cerium nanoparticles (CeO2 NPs), silver nanoparticles (Ag NPs), titanium dioxide nanoparticles (TiO2 NPs), and carbon nanoparticles (C NPs), have been reported in different plant species to play a role to improve the plant physiology and metabolic pathways under environmental stresses. Crop plants readily absorb the nanoparticles through the cellular machinery of different tissues and organs to take part in metabolic and growth processes. Nanoparticles promote the activity of a range of antioxidant enzymes, including catalase (CAT), peroxidase (POD), and superoxide dismutase (SOD), in plant species, which in turn improve the growth and development under stressful conditions. The present review focuses on the mode of action and signaling of nanoparticles to the plant systems and their positive impact on growth, development, and ROS scavenging potential. The appropriate elucidation on mechanisms of nanoparticles in plants leads to better growth and yields under stress conditions, which will ultimately lead to increased agricultural production

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)